Market capitalization | $9.90m |
Enterprise Value | $1.37m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.02 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-28.17m |
Free Cash Flow (TTM) Free Cash Flow | $-27.97m |
Cash position | $10.17m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a Vincerx Pharma Inc forecast:
3 Analysts have issued a Vincerx Pharma Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.07 -1.07 |
19%
19%
|
|
EBITDA | -27 -27 |
47%
47%
|
EBIT (Operating Income) EBIT | -28 -28 |
46%
46%
|
Net Profit | -27 -27 |
45%
45%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed Hamdy, Raquel Izumi, Tom Thomas, Stuart Hwang, and John Byrd in 2018 and is headquartered in Palo Alto, CA.
Head office | United States |
CEO | Ahmed Hamdy |
Employees | 42 |
Founded | 2018 |
Website | vincerx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.